Trial · NCT04621565
Hydrocortisone Use During Peri-operation for Pituitary Adenomas
NCT04621565, Not applicable, Unknown, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hydrocortisone Use During Peri-operation for Pituitary Adenomas. Trials, record NCT04621565. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04621565
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hydrocortisone Use During Peri-operation for Pituitary Adenomas
- NCT number
- NCT04621565
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 436 participants, estimated
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- Pituitary Adenoma, Adrenal Insufficiency, Surgery
- Interventions
- Normal saline, Hydrocortisone
- First posted
- 2020-11-09
- Last updated
- 2020-11-09
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of newly-onset adrenal insufficiency | During the first 3 postoperative days | Adrenal insufficiency: lower-than-normal serum cortisol level at 8 a.m., plus the following related symptoms, including serious fatigue, muscle weakness, decreased appetite, nausea, vomiting, diarrhea, low blood pressure, palpitation, and fever. |
| Secondary | Rate of newly-onset adrenal insufficiency | From the 3rd postoperative day to the 3rd postoperative month | Adrenal insufficiency: lower-than-normal serum cortisol level at 8 a.m., plus the following related symptoms, including serious fatigue, muscle weakness, decreased appetite, nausea, vomiting, diarrhea, low blood pressure, palpitation, and fever. |
| Other | Rate of newly-developed diabetes mellitus | During the first 3 postoperative months | A random reading of blood sugar level more than 200 mg/dL (11.1 mmol/L), or a reading after two hours (after OGTT) over 200 mg/dL (11.1 mmol/L) indicates diabetes mellitus. |
| Other | Rate of newly-developed diabetes insipidus | During the first 3 postoperative months | Urine volume \> 300ml for more than 3h or \> 6 liter per day, specific gravity of urine \<1.003, and serum sodium levels \> 145 mmol/L indicate diabetes insipidus. |
| Other | Concentration of blood electrolytes | At the 3rd postoperative month | The level of Na+, K+, and Ca++ in the blood |
| Other | Concentration of blood cells | At the 3rd postoperative month | Numbers of erythrocytes, leukocytes, neutrophils, lymphocytes, thrombocytes in the blood |
| Other | Percentage of blood cells | At the 3rd postoperative month | Percentage of neutrophils, monocytes, lymphocytes of the leukocytes |
| Other | Concentration of indexes of coagulation function #1 | At the 3rd postoperative month | Prothrombin time, activated partial thromboplastin time, and thrombin time |
| Other | Level of international normalized ratio | At the 3rd postoperative month | Level of international normalized ratio |
| Other | Level of D-Dimer | At the 3rd postoperative month | Level of D-Dimer |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04621565
GET https://conductscience.org/api/trials/v1/NCT04621565/registered